Figure 3. Interaction between Tregs and other cells in HBV-related liver disease
References
[1] Seto W K, Lo Y R, Pawlotsky J M,Yuen M F. Chronic hepatitis B virus infection [J]. Lancet,2018, 392 (10161): 2313-2324.
[2] Schweitzer A, Horn J, Mikolajczyk R T, Krause G,Ott J J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 [J]. Lancet, 2015, 386 (10003): 1546-1555.
[3] Zhan Q, Xu J H, Yu Y Y, Lo Kk E, El-Nezami H,Zeng Z. Human immune repertoire in hepatitis B virus infection [J]. World J Gastroenterol, 2021, 27 (25): 3790-3801.
[4] The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet Gastroenterol Hepatol, 2020, 5 (3): 245-266.
[5] WHO Guidelines Approved by the Guidelines Review Committee , in Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection . 2015, World Health Organization, 2015.: Geneva.
[6] Shi Y,Zheng M. Hepatitis B virus persistence and reactivation [J]. Nat Rev Immunol,2020, 370: m2200.
[7] Yuen M-F, Chen D-S, Dusheiko G M, Janssen H L A, Lau D T Y, Locarnini S A, et al.Lai C-L. Hepatitis B virus infection [J]. Nature Reviews Disease Primers, 2018, 4: 18035.
[8] Fattovich G, Bortolotti F,Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors [J]. J Hepatol,2008, 48 (2): 335-352.
[9] Choi Y S, Lee J, Lee H W, Chang D Y, Sung P S, Jung M K, et al.Shin E C. Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis [J]. Gut, 2015, 64 (8): 1303-1313.
[10] Plitas G,Rudensky A Y. Regulatory T Cells: Differentiation and Function [J]. Cancer Immunol Res, 2016, 4 (9): 721-725.
[11] Sakaguchi S, Mikami N, Wing J B, Tanaka A, Ichiyama K,Ohkura N. Regulatory T Cells and Human Disease [J]. Annu Rev Immunol, 2020, 38: 541-566.
[12] Wing J B, Tanaka A,Sakaguchi S. Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer [J]. Immunity, 2019, 50 (2): 302-316.
[13] Leonard J D, Gilmore D C, Dileepan T, Nawrocka W I, Chao J L, Schoenbach M H, et al.Savage P A. Identification of Natural Regulatory T Cell Epitopes Reveals Convergence on a Dominant Autoantigen [J]. Immunity, 2017, 47 (1): 107-117.e108.
[14] Thornton A M, Lu J, Korty P E, Kim Y C, Martens C, Sun P D,Shevach E M. Helios(+) and Helios(-) Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires [J]. Eur J Immunol, 2019, 49 (3): 398-412.
[15] Abbas A K, Benoist C, Bluestone J A, Campbell D J, Ghosh S, Hori S, et al.Ziegler S F. Regulatory T cells: recommendations to simplify the nomenclature [J]. Nat Immunol, 2013, 14 (4): 307-308.
[16] Chen W, Jin W, Hardegen N, Lei K J, Li L, Marinos N, et al.Wahl S M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 [J]. J Exp Med, 2003, 198 (12): 1875-1886.
[17] Schmetterer K G, Neunkirchner A,Pickl W F. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation [J]. Faseb j, 2012, 26 (6): 2253-2276.
[18] Fontenot J D, Gavin M A,Rudensky A Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells [J]. Nat Immunol, 2003, 4 (4): 330-336.
[19] Khattri R, Cox T, Yasayko S A,Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells [J]. Nat Immunol, 2003, 4 (4): 337-342.
[20] Hori S, Nomura T,Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3 [J]. Science, 2003, 299 (5609): 1057-1061.
[21] Mills K H. Regulatory T cells: friend or foe in immunity to infection? [J]. Nat Rev Immunol, 2004, 4 (11): 841-855.
[22] Billerbeck E, Bottler T,Thimme R. Regulatory T cells in viral hepatitis [J]. World J Gastroenterol, 2007, 13 (36): 4858-4864.
[23] Liu W, Putnam A L, Xu-Yu Z, Szot G L, Lee M R, Zhu S, et al.Bluestone J A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells [J]. J Exp Med, 2006, 203 (7): 1701-1711.
[24] Arroyo Hornero R, Betts G J, Sawitzki B, Vogt K, Harden P N,Wood K J. CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression [J]. Transplantation, 2017, 101 (2): 302-309.
[25] Shitara K,Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy [J]. Ann N Y Acad Sci, 2018, 1417 (1): 104-115.
[26] Marfil-Garza B A, Hefler J, Bermudez De Leon M, Pawlick R, Dadheech N,Shapiro A M J. Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation [J]. Endocr Rev, 2021, 42 (2): 198-218.
[27] Jin S, Sun S, Ling H, Ma J, Zhang X, Xie Z, et al.Wang J. Protectin DX restores Treg/T(h)17 cell balance in rheumatoid arthritis by inhibiting NLRP3 inflammasome via miR-20a [J]. 2021, 12 (3): 280.
[28] Yang X, Lun Y, Jiang H, Liu X, Duan Z, Xin S,Zhang J. SIRT1-Regulated Abnormal Acetylation of FOXP3 Induces Regulatory T-Cell Function Defect in Hashimoto’s Thyroiditis [J]. Thyroid, 2018, 28 (2): 246-256.
[29] Zheng C, Zheng L, Yoo J K, Guo H, Zhang Y, Guo X, et al.Zhang Z. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing [J]. Cell,2017, 169 (7): 1342-1356.e1316.
[30] Ichai P,Samuel D. Management of Fulminant Hepatitis B [J]. Curr Infect Dis Rep, 2019, 21 (7): 25.
[31] Liang T J. Hepatitis B: the virus and disease [J]. Hepatology, 2009, 49 (5 Suppl): S13-21.
[32] Wright T L,Lau J Y. Clinical aspects of hepatitis B virus infection [J]. Lancet, 1993, 342 (8883): 1340-1344.
[33] Mason W S, Gill U S, Litwin S, Zhou Y, Peri S, Pop O, et al.Kennedy P T. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant [J]. Gastroenterology, 2016, 151 (5): 986-998.e984.
[34] Vignali D A, Collison L W,Workman C J. How regulatory T cells work [J]. Nat Rev Immunol, 2008, 8 (7): 523-532.
[35] Park R, Winnicki M, Liu E,Chu W M. Immune checkpoints and cancer in the immunogenomics era [J]. Brief Funct Genomics, 2019, 18 (2): 133-139.
[36] Qureshi O S, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt E M, et al.Sansom D M. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 [J]. Science, 2011, 332 (6029): 600-603.
[37] Chikuma S. CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation [J]. Curr Top Microbiol Immunol, 2017, 410: 99-126.
[38] Grover P, Goel P N,Greene M I. Regulatory T Cells: Regulation of Identity and Function [J]. Front Immunol, 2021, 12: 750542.
[39] Arce-Sillas A, Álvarez-Luquín D D, Tamaya-Domínguez B, Gomez-Fuentes S, Trejo-García A, Melo-Salas M, et al.Adalid-Peralta L. Regulatory T Cells: Molecular Actions on Effector Cells in Immune Regulation [J]. J Immunol Res, 2016, 2016: 1720827.
[40] Klocke K, Sakaguchi S, Holmdahl R,Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood [J]. 2016, 113 (17): E2383-2392.
[41] PD-L1 regulates the development m, and function of induced regulatory T cellsSheppard, K. A., Fitz L J, Lee J M, Benander C, George J A, Wooters J, et al.Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta [J]. FEBS Lett, 2004, 574 (1-3): 37-41.
[42] CD73 as a potential opportunity for cancer immunotherapyFrancisco L M, Salinas V H, Brown K E, Vanguri V K, Freeman G J, Kuchroo V K,Sharpe A H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells [J]. J Exp Med, 2009, 206 (13): 3015-3029.
[43] Ghalamfarsa G,Kazemi M H. CD73 as a potential opportunity for cancer immunotherapy [J]. Expert Opin Ther Targets, 2019, 23 (2): 127-142.
[44] Allard B, Longhi M S, Robson S C,Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets [J]. Immunol Rev, 2017, 276 (1): 121-144.
[45] Antonioli L, Pacher P, Vizi E S,Haskó G. CD39 and CD73 in immunity and inflammation [J]. Trends Mol Med, 2013, 19 (6): 355-367.
[46] Gavin M A, Rasmussen J P, Fontenot J D, Vasta V, Manganiello V C, Beavo J A,Rudensky A Y. Foxp3-dependent programme of regulatory T-cell differentiation [J]. Nature, 2007, 445 (7129): 771-775.
[47] Cekic C,Linden J. Purinergic regulation of the immune system [J]. Nat Rev Immunol, 2016, 16 (3): 177-192.
[48] Huang C T, Workman C J, Flies D, Pan X, Marson A L, Zhou G, et al.Vignali D A. Role of LAG-3 in regulatory T cells [J]. Immunity, 2004, 21 (4): 503-513.
[49] Yang Z Z, Kim H J, Wu H, Jalali S,Tang X. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma [J]. Clin Cancer Res, 2020, 26 (19): 5217-5231.
[50] Manieri N A, Chiang E Y,Grogan J L. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle [J]. Trends Immunol, 2017, 38 (1): 20-28.
[51] TIGIT as a Promising Therapeutic Target in Autoimmune DiseasesTIGIT as a Promising Therapeutic Target in Autoimmune DiseasesStanietsky N, Rovis T L, Glasner A, Seidel E, Tsukerman P, Yamin R, et al.Mandelboim O. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR [J]. Eur J Immunol, 2013, 43 (8): 2138-2150.
[52] Yue C, Gao S, Li S, Xing Z, Qian H, Hu Y, et al.Hua C. TIGIT as a Promising Therapeutic Target in Autoimmune Diseases [J]. Front Immunol, 2022, 13: 911919.
[53] Huang Y H, Zhu C, Kondo Y, Anderson A C, Gandhi A, Russell A, et al.Blumberg R S. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion [J]. Nature, 2015, 517 (7534): 386-390.
[54] CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+Liu Z, McMichael E L, Shayan G, Li J, Chen K, Srivastava R, et al.Ferris R L. Novel Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients [J]. Clin Cancer Res, 2018, 24 (18): 4529-4538.
[55] Smyth L A, Ratnasothy K, Tsang J Y, Boardman D, Warley A, Lechler R,Lombardi G. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function [J]. Eur J Immunol,2013, 43 (9): 2430-2440.
[56] Changes in circulating TCF1- and GARP-associated regulatory T cell subsets reflect the clinicalInvestigation of Regulatory T Cells and Secreted Tuyji Tok Y, Şener A G, Aksoy Gökmen A, Demirdal T,Kaya S. [Investigation of Regulatory T Cells and Secreted Immunomodulatory Cytokine IL-10 Levels in Patients with Hepatitis B] [J]. Mikrobiyol Bul, 2020, 54 (2): 266-278.
[57] Shao X, Ma J, Jia S, Yang L, Wang W,Jin Z. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection [J]. Front Cell Infect Microbiol, 2017, 7: 472.
[58] Qiu H, Wang N, Lin D, Yuan Y, Li J, Mao D,Meng Y. The positive feedback loop of furin and TGFβ1 enhances the immune responses of Tregs to hepatocellular carcinoma cells and hepatitis B virus in vitro [J]. Cell Biol Int, 2022, 46 (8): 1215-1226.
[59] Li X, Liu X,Wang W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases [J]. Front Cell Dev Biol, 2021, 9: 614847.
[60] Thornton A M, Donovan E E, Piccirillo C A,Shevach E M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function [J]. J Immunol, 2004, 172 (11): 6519-6523.
[61] Zhao H, Liao X,Kang Y. Tregs: Where We Are and What Comes Next? [J]. Front Immunol,2017, 8: 1578.
[62] Zhao H J, Hu Y F, Han Q J,Zhang J. Innate and adaptive immune escape mechanisms of hepatitis B virus [J]. Cancers (Basel), 2022, 28 (9): 881-896.
[63] Yang G, Wan P, Zhang Y, Tan Q, Qudus M S, Yue Z, et al.Li Y. Innate Immunity, Inflammation, and Intervention in HBV Infection [J]. 2022, 14 (10).
[64] Zheng J, Ou Z, Xu Y, Xia Z, Lin X, Jin S, et al.Wu J. Hepatitis B virus-specific effector CD8(+) T cells are an important determinant of disease prognosis: A meta-analysis [J]. Vaccine, 2019, 37 (18): 2439-2446.
[65] Asabe S, Wieland S F, Chattopadhyay P K, Roederer M, Engle R E, Purcell R H,Chisari F V. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection [J]. J Virol, 2009, 83 (19): 9652-9662.
[66] Shin E C, Sung P S,Park S H. Immune responses and immunopathology in acute and chronic viral hepatitis [J]. Nat Rev Immunol, 2016, 16 (8): 509-523.
[67] Guidotti L G, Rochford R, Chung J, Shapiro M, Purcell R,Chisari F V. Viral clearance without destruction of infected cells during acute HBV infection [J]. Science, 1999, 284 (5415): 825-829.
[68] Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al.Protzer U. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis [J]. Gastroenterology, 2016, 150 (1): 194-205.
[69] Stoop J N, van der Molen R G, Baan C C, van der Laan L J, Kuipers E J, Kusters J G,Janssen H L. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection [J]. Hepatology, 2005, 41 (4): 771-778.
[70] Feng I C, Koay L B, Sheu M J, Kuo H T, Sun C S, Lee C, et al.Tsai S L. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection [J]. J Biomed Sci, 2007, 14 (1): 43-57.
[71] TrehanPati N, Geffers R, Sukriti, Hissar S, Riese P, Toepfer T, et al.Sarin S K. Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection [J]. Hepatology, 2009, 49 (3): 781-790.
[72] Peng G, Li S, Wu W, Sun Z, Chen Y,Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection [J]. Immunology, 2008, 123 (1): 57-65.
[73] Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, et al.Wang F S. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B [J]. J Immunol, 2006, 177 (1): 739-747.
[74] Characterization of the Treg Response in the Hepatitis B Virus Hydrodynamic Injection MouseStross L, Günther J, Gasteiger G, Asen T, Graf S, Aichler M, et al.Protzer U. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice [J]. Hepatology, 2012, 56 (3): 873-883.
[75] Dietze K K, Schimmer S, Kretzmer F, Wang J, Lin Y, Huang X, et al.Liu J. Characterization of the Treg Response in the Hepatitis B Virus Hydrodynamic Injection Mouse Model [J]. PLoS One, 2016, 11 (3): e0151717.
[76] Kosinska A D, Pishraft-Sabet L, Wu W, Fang Z, Lenart M, Chen J, et al.Lu M. Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models [J]. Hepatology, 2017, 66 (1): 69-83.
[77] Zou S,Du Y. Simultaneous or Prior Activation of Intrahepatic Type I Interferon Signaling Leads to Hepatitis B Virus Persistence in a Mouse Model [J]. 2021, 95 (24): e0003421.
[78] Littman D R,Rudensky A Y. Th17 and regulatory T cells in mediating and restraining inflammation [J]. Cell, 2010, 140 (6): 845-858.
[79] Zelinskyy G, Dietze K, Sparwasser T,Dittmer U. Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus [J]. PLoS Pathog, 2009, 5 (8): e1000406.
[80] Xu L, Xia C, Long Y, Liu C, Lu S, Song Y, et al.Zou W. Regulatory T cells and T helper 17 cells in viral infection [J]. Hepatol Res, 2020, 91 (5): e12873.
[81] Cheng X, Shan Y Y,Luo Y W. [Dynamic change in Th17/regulatory T cell ratio in peripheral blood of patients with acute hepatitis B and its significance] [J]. Zhonghua Gan Zang Bing Za Zhi, 2016, 24 (8): 565-568.
[82] Bahabayi A, Zeng X, Tuerhanbayi B, Zhang Y, Hasimu A, Guo S, et al.Liu C. Changes in circulating TCF1- and GARP-associated regulatory T cell subsets reflect the clinical status of patients with chronic HBV infection [J]. 2022, 211 (5-6): 237-247.
[83] Liu C. Increased proportion of functional subpopulations in circulating regulatory T cells in patients with chronic hepatitis B [J]. Medicine (Baltimore),2020, 50 (4): 439-452.
[84] Tang R, Lei Z, Wang X, Qi Q, He J, Liu D, et al.Su C. Hepatitis B envelope antigen increases Tregs by converting CD4+CD25(-) T cells into CD4(+)CD25(+)Foxp3(+) Tregs [J]. Exp Ther Med, 2020, 20 (4): 3679-3686.
[85] Giadans C G, Ríos D A, Ameigeiras B, Pietrantonio A M, Lucatelli N L, Haddad L, et al.Preciado M V. Chronic hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage [J]. J Viral Hepat, 2019, 26 (6): 727-737.
[86] Li J, Qiu S J, She W M, Wang F P, Gao H, Li L, et al.Jiang W. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis [J]. PLoS One, 2012, 7 (6): e39307.
[87] Niu Y, Liu H, Yin D, Yi R, Chen T, Xue H, et al.Zhao Y. The balance between intrahepatic IL-17(+) T cells and Foxp3(+) regulatory T cells plays an important role in HBV-related end-stage liver disease [J]. BMC Immunol, 2011, 12: 47.
[88] Zeng X, Bahabayi A, Tuerhanbayi B, Zheng M, Liu T, Xu L, et al.Liu C. The altered HLA-DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells [J]. Med Microbiol Immunol, 2022, 29 (5): 340-351.
[89] chronic hepatitis B Franzese, O. R T c a I-T h c e i p w c h B R T c a I-T h c e i p w, Kennedy P T, Gehring A J, Gotto J, Williams R, Maini M K,Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection [J]. J Virol,2005, 79 (6): 3322-3328.
[90] Feng H, Yin J, Han Y P, Zhou X Y, Chen S, Yang L, et al.Zhang G X. Regulatory T cells and IL-17(+) T helper cells enhanced in patients with chronic hepatitis B virus infection [J]. Int J Clin Exp Med, 2015, 8 (6): 8674-8685.
[91] Ichikawa S, Mucida D, Tyznik A J, Kronenberg M,Cheroutre H. Hepatic stellate cells function as regulatory bystanders [J]. J Immunol, 2011, 186 (10): 5549-5555.
[92] Up-regulated DNA-binding inhibitor Id3 promotes differentiation of regulatoryLi W, Han J,Wu H. Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression [J]. Chronic Dis Transl Med, 2016, 2 (2): 67-80.
[93] Liu C, Zeng X, Yu S, Ren L, Sun X, Long Y, et al.Zhang Y. Up-regulated DNA-binding inhibitor Id3 promotes differentiation of regulatory T cell to influence antiviral immunity in chronic hepatitis B virus infection [J]. Life Sci, 2021, 285: 119991.
[94] Al-Bari M A A. A current view of molecular dissection in autophagy machinery [J]. J Physiol Biochem, 2020, 76 (3): 357-372.
[95] Wei J, Long L, Yang K, Guy C, Shrestha S, Chen Z, et al.Chi H. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis [J]. Nat Immunol, 2016, 17 (3): 277-285.
[96] Cheng L S, Li J, Liu Y, Wang F P, Wang S Q, She W M, et al.Jiang W. HMGB1-induced autophagy: a new pathway to maintain Treg function during chronic hepatitis B virus infection [J]. Clin Sci (Lond), 2017, 131 (5): 381-394.
[97] Hu C C, Jeng W J, Chen Y C, Fang J H, Huang C H, Teng W, et al.Chien R N. Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction [J]. Sci Rep, 2017, 7 (1): 15280.
[98] Hong J,Gong Z J. Human plasmacytoid dendritic cells from patients with chronic hepatitis B virus infection induce the generation of a higher proportion of CD4(+) and CD25(+) regulatory T cells compared with healthy patients [J]. Hepatol Res, 2008, 38 (4): 362-373.
[99] Acute-on-chronic liver failure: terminology m a m, Y., Yuan X D, Liu H H, Xiang L, Chen L M, Fan Y C, et al.Wang K. 5-Aza-2’-deoxycytidine may enhance the frequency of T regulatory cells from CD4(+) naïve T cells isolated from the peripheral blood of patients with chronic HBV infection [J]. Clin Exp Immunol, 2021, 17 (2): 177-185.
[100] Sarin S K,Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management [J]. Nat Rev Gastroenterol Hepatol, 2016, 13 (3): 131-149.
[101] Chen T, Yang Z, Choudhury A K, Al Mahtab M, Li J, Chen Y, et al.Ning Q. Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region [J]. Hepatol Int, 2019, 13 (6): 695-705.
[102] Wang F, Sun W, Xiao Q, Liang C, Jiang S, Lian Y, et al.Zheng S. Peripheral T lymphocytes predict the severity and prognosis in patients with HBV-related acute-on-chronic liver failure [J]. Medicine (Baltimore),2021, 100 (5): e24075.
[103] Yang L, Jia S, Shao X, Liu S, Zhang Q, Song J, et al.Jin Z. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection [J]. Virol J, 2019, 16 (1): 48.
[104] Tan N H, Chen B, J. P,S. D. Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure at Different Disease Stages [J]. Biomed Res Int, 2021, 2021: 9140602.
[105] Xue-Song L, Cheng-Zhong L, Ying Z,Mo-Bin W. Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection [J]. BMC Gastroenterol, 2012, 12: 43.
[106] Liang X S, Li C Z, Zhou Y, Yin W, Liu Y Y,Fan W H. Changes in circulating Foxp3(+) regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure [J]. World J Gastroenterol,2014, 20 (26): 8558-8571.
[107] Niu Y H, Yin D L, Liu H L, Yi R T, Yang Y C, Xue H A, et al.Zhao Y R. Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure [J]. World J Gastroenterol, 2013, 19 (26): 4146-4154.
[108] Zhang G L, Xie D Y, Lin B L, Xie C, Ye Y N, Peng L, et al.Gao Z L. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure [J]. 4.3-J Gastroenterol Hepatol, 2013, 28 (3): 513-521.
[109] Mak L Y, Cheung K S, Fung J, Seto W K,Yuen M F. New strategies for the treatment of chronic hepatitis B [J]. Trends Mol Med, 2022, 28 (9): 742-757.
[110] Jiang Y, Li W, Yu L, Liu J, Xin G, Yan H, et al.Niu J. Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies [J]. 22-Cell Mol Immunol, 2011, 8 (1): 75-82.
[111] Pang X, Zhang L, Liu N, Liu B, Chen Z, Li H, et al.Hu P. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients [J]. Clin Exp Immunol, 2020, 202 (1): 80-92.
[112] Zhang Y R, Li B, Wang C X, Zhou N, Qi W, Li X L, et al.Zhang Y D. Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs [J]. Braz J Med Biol Res, 2017, 50 (3): e5796.
[113] Lan Y T, Wang Z L, Tian P, Gong X N, Fan Y C,Wang K. Treg/Th17 imbalance and its clinical significance in patients with hepatitis B-associated liver cirrhosis [J]. Scand J Immunol, 2019, 14 (1): 114.
[114] Liu N, Liu B, Zhang L, Li H, Chen Z, Luo A, et al.Hu P. Recovery of circulating CD56(dim) NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg [J]. Int Immunopharmacol, 2018, 62: 59-66.
[115] Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, et al.Wei H. Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy [J]. Can J Gastroenterol Hepatol, 2021, 6 (1): 376.
[116] Alberts C J, Clifford G M, Georges D, Negro F, Lesi O A, Hutin Y J,de Martel C. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review [J]. Lancet Gastroenterol Hepatol, 2022, 7 (8): 724-735.
[117] Deng Z, Zhou J, Mu X, Gu J, Li X, Shao Q, et al.Xia Y. Regulatory T Cells Improved the Anti-cirrhosis Activity of Human Amniotic Mesenchymal Stem Cell in the Liver by Regulating the TGF-β-Indoleamine 2,3-Dioxygenase Signaling [J]. Front Cell Dev Biol, 2021, 9: 737825.
[118] Cho H J,JY. C. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma [J]. Int J Mol Sci, 2021, 22 (15): 8011.
[119] Li X, Su Y, Hua X, Xie C, Liu J, Huang Y, et al.Gao Z. Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis [J]. J Transl Med, 2017, 15 (1): 75.
[120] Moreau J M, Velegraki M, Bolyard C, Rosenblum M D,Li Z. Transforming growth factor-β1 in regulatory T cell biology [J]. Sci Immunol, 2022, 7 (69): eabi4613.
[121] Huang Y H, Chen Y X, Zhang L J, Chen Z X,Wang X Z. Hydrodynamics-based transfection of rat interleukin-10 gene attenuates porcine serum-induced liver fibrosis in rats by inhibiting the activation of hepatic stellate cells [J]. Int J Mol Med, 2014, 34 (3): 677-686.
[122] Yu X, Guo R, Ming D, Su M, Lin C, Deng Y, et al.Su Z. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-β1/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis [J]. J Gastroenterol Hepatol, 2014, 29 (5): 1065-1072.
[123] Li K, Liu H,Guo T. Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients [J]. Clin Res Hepatol Gastroenterol, 2017, 41 (4): 399-407.
[124] Mou H, Wu S, Zhao G,Wang J. Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation [J]. Exp Ther Med, 2019, 17 (4): 2963-2968.
[125] Sagnelli E,Macera M. Epidemiological and etiological variations in hepatocellular carcinoma [J]. Infection, 2020, 48 (1): 7-17.
[126] Lim C J, Lee Y H, Pan L, Lai L, Chua C, Wasser M, et al.Chew V. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma [J]. Gut, 2019, 68 (5): 916-927.
[127] Wada Y, Nakashima O, Kutami R, Yamamoto O,Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration [J]. Hepatology, 1998, 27 (2): 407-414.
[128] Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al.Wang F S. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients [J]. Gastroenterology, 2007, 132 (7): 2328-2339.
[129] Zhang H H, Mei M H, Fei R, Liu F, Wang J H, Liao W J, et al.Chen H S. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses [J]. J Viral Hepat, 2010, 17 Suppl 1: 34-43.
[130] Zhang X, Gao L, Liang X, Guo M, Wang R, Pan Y, et al.Ma C. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes [J]. Liver Int, 2015, 35 (3): 1087-1094.
[131] Tough D F, Rioja I, Modis L K,Prinjha R K. Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications [J]. Trends Immunol, 2020, 41 (1): 29-45.
[132] Nishida N, Kudo M, Gao Y, You M, Fu J, Tian M, et al.Yang P. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B [J]. J Histochem Cytochem,2022, 76 (1): 148-159.
[133] Yang P, Li Q J, Feng Y, Zhang Y, Markowitz G J, Ning S, et al.Wang X F. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma [J]. Cancer Cell, 2012, 22 (3): 291-303.
[134] Zhang C, Gao Y, Du C,Markowitz G J. Hepatitis B-Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation [J]. Biomed Res Int, 2021, 81 (9): 2386-2398.
[135] Tian Z, Chen Y,Gao B. Natural killer cells in liver disease [J]. Hepatology, 2013, 57 (4): 1654-1662.
[136] Chen Y, Sun R, Wu X, Cheng M, Wei H,Tian Z. CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40 [J]. J Innate Immun, 2016, 8 (1): 30-42.
[137] Liu N, Chang C W, Steer C J, Wang X W,Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells [J]. Gastroenterology, 2022, 162 (2): 575-589.
[138] Wu Q, Zhou W, Yin S, Zhou Y, Chen T, Qian J, et al.Zheng S. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer [J]. Sci Rep, 2019, 70 (1): 198-214.
[139] Dawidowicz M, Kula A, Mielcarska S,Kiczmer P. B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating Lymphocytes [J]. cells, 2023, 12 (6): 861.
[140] Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al.Zou W. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells [J]. J Immunol, 2006, 177 (1): 40-44.
[141] Yu X, Harden K, Gonzalez L C, Francesco M, Chiang E, Irving B, et al.Grogan J L. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells [J]. Nat Immunol,2009, 10 (1): 48-57.
[142] Zheng M, Sun R, Wei H,Tian Z. NK Cells Help Induce Anti-Hepatitis B Virus CD8+ T Cell Immunity in Mice [J]. J Immunol, 2016, 196 (10): 4122-4131.
[143] Liu S, Xu C, Yang F, Zong L, Qin Y, Gao Y, et al.Zheng M. Natural Killer Cells Induce CD8(+) T Cell Dysfunction via Galectin-9/TIM-3 in Chronic Hepatitis B Virus Infection [J]. Front Immunol, 2022, 13: 884290.
[144] Ma Q, Dong X, Liu S, Zhong T, Sun D, Zong L, et al.Zheng M. Hepatitis B e Antigen Induces NKG2A(+) Natural Killer Cell Dysfunction via Regulatory T Cell-Derived Interleukin 10 in Chronic Hepatitis B Virus Infection [J]. Front Cell Dev Biol, 2020, 8: 421.
[145] Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, et al.Tian Z. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer [J]. Oncoimmunology, 2017, 6 (1): e1264562.
[146] Romano M, Fanelli G, Albany C J, Giganti G,Lombardi G. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity [J]. Front Immunol, 2019, 10: 43.
[147] Topalian S L, Drake C G,Pardoll D M. Immune checkpoint blockade: a common denominator approach to cancer therapy [J]. Cancer Cell, 2015, 27 (4): 450-461.
[148] Langhans B. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma [J]. Cancer Med, 2019, 68 (12): 2055-2066.
[149] Wu J F, Wu T C, Chen C H, Ni Y H, Chen H L, Hsu H Y,Chang M H. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion [J]. Gastroenterology, 2010, 138 (1): 165-172.e161-163.
[150] Karkhah A, Javanian M,Ebrahimpour S. The role of regulatory T cells in immunopathogenesis and immunotherapy of viral infections [J]. Infect Genet Evol,2018, 59: 32-37.
[151] Wen H, Liu Y, Wang S, Wang T, Zhang G, Chen X, et al.Cui H. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents [J]. Molecules, 2019, 24 (11).
[152] He W, Hao S, Dong X, Zhang D,Jia Z. Circulating cytokine profile and modulation of regulatory T cells in chronic hepatitis B patients with type 2 diabetes mellitus [J]. Biomol Biomed, 2022, 23 (1): 53-62.
[153] Huang M, Huang X,Huang N. Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells [J]. Cancer Sci,2022, 113 (6): 1968-1983.
[154] Kim H D, Song G W, Park S, Jung M K, Kim M H, Kang H J, et al.Park S H. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and Features of Hepatocellular Carcinoma [J]. Gastroenterology,2018, 155 (6): 1936-1950.e1917.
[155] Tan N H,Chen B. Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure at Different Disease Stages [J]. 2021, 2021: 9140602.
[156] Fang Y, Yuan X D, Liu H H, Xiang L, Chen L M, Fan Y C, et al.Wang K. 5-Aza-2’-deoxycytidine may enhance the frequency of T regulatory cells from CD4(+) naïve T cells isolated from the peripheral blood of patients with chronic HBV infection [J]. Expert Rev Clin Immunol, 2021, 17 (2): 177-185.